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Abstract Randomized phase III trials have shown significant
improvementof survival 1,2, and 3 years after implantationof
1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers for
patients with newly diagnosed malignant glioma. But these
studies and subsequent non-phase III studies have also shown
risks associated with local chemotherapy within the central
nervous system. The introduction of concomitant radiochemo-
therapy with temozolomide (TMZ) has later demonstrated a
survival benefit in a phase III trial and has become the current
treatment standard for newly diagnosed malignant glioma
patients. Lately, this has resulted in clinical protocols combin-
ing local chemotherapy with BCNU wafers and concomitant
radiochemotherapy with TMZ although this may carry the risk
of increased toxicity. We have compiled the treatment
experience of seven neurosurgical centers using implantation
of carmustine wafers at primary surgery followed by 6 weeks
of radiation therapy (59–60 Gy) and 75 mg/m
2/day TMZ in
patients with newly diagnosed glioblastoma followed by
TMZ monochemotherapy. We have retrospectively analyzed
the postoperative clinical course, occurrence and severity of
adverse events, progression-free interval, and overall survival
in 44 patients with newly diagnosed glioblastoma multiforme.
All patients received multimodal treatment including tumor
resection, BCNU wafer implantation, and concomitant radio-
chemotherapy. Of 44 patients (mean age 59±10.8 years) with
glioblastoma who received Gliadel wafer at primary surgery,
28 patients (64%) had died, 16 patients (36%) were alive, and
15 patients showed no evidence of clinical or radiographic
progression after a median follow-up of 15.6 months. At time
of analysis of adverse events in this patient population, the
median overall survival was 12.7 months and median
progression-free survival was 7.0 months. Surgical, neurolog-
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DOI 10.1007/s10143-010-0280-7ical, and medical adverse events were analyzed. Twenty-three
patients (52%) experienced adverse events of any kind
including complications that did not require treatment.
Nineteen patients (43%) experienced grade 3 or grade 4
adverse events. Surgical complications included cerebral
edema, healing abnormalities, cerebral spinal fluid
leakage, meningitis, intracranial abscess, and hydroceph-
alus. Neurological adverse events included newly diag-
nosed seizures, alteration of mental status, and new
neurological deficits. Medical complications were throm-
boembolic events (thrombosis, pulmonary embolism) and
hematotoxicity. Combination of both treatment strategies,
local chemotherapy with BCNU wafer and concomitant
radiochemotherapy, appears attractive in aggressive mul-
timodal treatment schedules and may utilize the sensitiz-
ing effect of TMZ and carmustine on MGMT and AGT
on their respective drug resistance genes. Our data
demonstrate that combination of local chemotherapy
and concomitant radiochemotherapy carries a significant
risk of toxicity that currently appears underestimated.
Adverse events observed in this study appear similar to
complication rates published in the phase III trials for
BCNU wafer implantation followed by radiation therapy
alone, but further add the toxicity of concomitant
radiochemotherapy with systemic TMZ. Save use of a
combined approach will require specific prevention
strategies for multimodal treatments.
Keywords Glioma.Local chemotherapy.BCNU.
Carmustine.Gliadel.Temozolomide.Radiochemotherapy
Introduction
Over the past years, few advances have been made improving
progression-free survival (PFS) and overall survival (OAS) of
patients with newly diagnosed malignant glioma. 1,3-bis (2-
Chloroethyl)-1-nitrosourea (BCNU) wafer implantation directly
into the resection cavity follow e db yr a d i a t i o nt h e r a p yh a s
shown to significantly improve survival in patients with newly
diagnosed malignant glioma [25], and this survival benefit was
maintained over the long term [26]. For the subgroup of
glioblastoma, the treatment effect in this trail failed to reach
statistical significance. However, a meta-analysis combining
the results of the randomized phase III trial published by
Westphal et al. [25] and an earlier randomized phase III study
by Valtonen et al. [24] demonstrated that specifically for the
subgroup of glioblastoma treatment with BCNU wafers
resulted in a survival increase to 13.1 versus 10.9 months for
placebo patients (p=0.03). Representing class II evidence, the
results of the two trials lead to Food and Drug Administration
(FDA) approval of Gliadel in the treatment of newly diagnosed
glioblastoma in March 2003.
Biodegradable BCNU wafers (Gliadel®) remain the only
approved interstitial chemotherapy for treatment of newly
diagnosedmalignantgliomaandrecurrentglioblastomatoday.
More than 20,000 procedures of BCNU wafer implantation
into resection cavities have been performed worldwide since
the initial release of the product and FDA approval in 1996.
Surgically, local intracerebral chemotherapy using BCNU
wafers is straightforward, and it is not associated with
systemic toxicities [15, 16]. However, several complications
have been associated with implantation of BCNU wafer,
including cerebral edema, healing abnormalities, cerebral
spinal fluid (CSF) leaks, intracranial infections, seizures,
hydrocephalus, and cyst formation. The rates for these
adverse events (AE) were well established in two random-
ized phase III trials that tested BCNU wafers against placebo
wafers [15, 16]. Since the completion of these studies,
systemic chemotherapy for malignant gliomas has made
significant progress and has greatly impacted current
treatment standards. Stupp et al. demonstrated the efficacy
of radiation therapy and concomitant temozolomide in newly
diagnosed glioblastomas in a phase III trial [22]. After tumor
resection, a 6-week protocol of concomitant radiochemo-
therapy with temozolomide followed by six cycles of
temozolomide monochemotherapy can now be regarded as
the treatment standard for patients with newly diagnosed
glioblastoma [22]. Generally, this treatment is well tolerated.
In the pivotal phase III study of temozolomide in newly
diagnosed malignant gliomas, 4.2% of patients receiving
temozolomide plus radiotherapy experienced thromboembolic
events. The hematologic toxicities included pancytopenia,
thrombocytopenia, and neutropenia. Grades 3 and 4 hemato-
logic toxicity occurred in 16% of patients receiving chemo-
radiotherapy with temozolomide [22].
A combination of local BCNU wafer treatment and
concomitant radiochemotherapy with temozolomide
appears attractive not only because it merges successful
treatment strategies for malignant gliomas but it may also
take advantage of a sensitizing effect of temozolomide and
carmustine on their respective resistance genes MGMT and
AGT [18]. Only few data have become available on safety
and efficiency of combining local BCNU wafer-based
chemotherapy with systemic chemotherapy [10, 14, 17].
Temozolomide has been the most common treatment used
with BCNU wafers [1, 4, 7, 8, 10, 19]. Regimen in which
temozolomide was administered concomitantly with radio-
therapy 2–4 weeks after surgery with BCNU wafer
implantation and then followed by temozolomide mono-
chemotherapy has been assessed in small retrospective
studies [10, 11, 14, 19]. Further, Asher reported a protocol
in which temozolomide was administered for 5 days
beginning on postoperative day 4 [1], and a study by
Heery et al. used chemoradiotherapy with concomitant
temozolomide without additional cycles of a monochemo-
442 Neurosurg Rev (2010) 33:441–449therapy [8]. These retrospective studies reported no notable
increase in the toxicity of BCNU wafer implantation other
than the known systemic effects of temozolomide which
were mostly hematotoxic events. However, only a small
number of patients have been studied, and those studies did
not specifically focus on the analysis of adverse events
associated with multimodal treatment approaches [10, 13,
17, 20, 21]. Our own experiences in contrast indicate an
elevated risk of adverse events than reported in the above
studies. In this multicenter toxicity data collection, we
therefore have retrospectively analyzed adverse events and
the treatment experience of seven neurosurgical centers.
Forty-four patients were treated with intraoperative BCNU
wafer implantation followed by 6 weeks of daily radiation
therapy (59–60 Gy) and concomitant temozolomide (75 mg/
m
2/day) followed by a temozolomide monochemotherapy
(150–200 mg/m
2 on five consecutive days of a 28-day
cycle). All patients had histologically confirmed newly
diagnosed glioblastoma. This analysis is focused on compli-
cation rates and risk profiles of BCNU wafer implantation.
At time of data analysis, only preliminary survival data were
available because of a relatively short follow-up.
Patients and methods
We have analyzed the clinical course of 44 patients with
newly diagnosed glioblastoma WHO grade IV treated at
seven neurosurgical institutions. Inclusion criteria for this
study were written consent after careful information
concerning potential risks and benefits of BCNU wafers,
no previous treatment for malignant glioma (operations,
chemotherapy, or radiation), and confirmation of a WHO
grade IV glioblastoma in the frozen section during
operation. Inclusion of the patients for data analysis of
adverse events was based on the treatment decision of the
individual center. No other formal inclusion criteria
applied. All patients underwent initial microsurgical tumor
resection (14% planned partial resection) and implantation
of four to eight (mean 7.3±1.3) carmustine-containing
wafers (Gliadel Wafers, Archimedes Pharma, Reading,
UK) into the resection cavity. Within 4 weeks after
surgery, patients were started on oral temozolomide
(75 mg/m
2/day) and radiotherapy 1.8 Gy/day for 6 weeks
(total dose ranged from 59 to 60 Gy). Within 2–4w e e k s
after completion of the concomitant radiochemotherapy
protocol, patients received a temozolomide monochemo-
therapy (150–200 mg/m
2) for the first 5 days of a 28-day
cycle. Time period for data collection started at initial
surgery and ranged from August 2005 to August 2008.
Potential medical risk factors possibly influencing the
clinical course such as diabetes, peripheral vascular
disease, or myelosuppression were documented as well
as details in surgical techniques for wafer implantation.
Clinical data were collected anonymously by datasheet
evaluation and analyzed for the study endpoints. These
were incidence and grade of adverse events, impact on
scheduled oncological treatment, and overall survival and
progression-free survival defined by Kaplan–Meyer sur-
vival analysis. Adverse events were documented including
time of occurrence, severity, necessity of hospitalization,
and therapeutic measures taken. Reported adverse events
were grouped into surgical, neurological, and medical
adverse events and graded according to National Cancer
Institute (NCI) guidelines [3].
This study was not undertaken or designed to demon-
strate treatment efficacy but to analyze the risks associated
with multimodal treatments. However, for survival data
analysis at time of data collection including OAS and PFS,
Kaplan–Maier analyses were performed; other endpoints
were presented by descriptive statistics (WinStat, R. Fitch
Software, Bad Krozingen, Germany).
The study cohort included 44 patients (16 females, 28
males) with a mean age of 57±10.9 years (range 28–
74 years) and a mean Karnofsky performance score (KPS)
of 81±15.3% (range 20–100%) at the time of hospital
admission (Table 1). Medical risk factors in this patient
population included diabetes mellitus in six (14%) patients,
peripheral vascular disease in two (5%) patients, and
myelosuppression in two (5%) patients. Surgical risk
factors included opening of the ventricular system in 13
patients (30%) and necessity of a dural patch in 28 patients
(64%). Thirty-seven patients (84%) received perioperative
prophylactic antibiotic treatment (Table 1).
Results
At the time of data analysis, 28 patients (64%) had died and
16 patients (36%) were alive with a median follow-up of
Table 1 Baseline demographic characteristics
Mean (SE) N (%) Range
Age 57±10.9 28–74
Karnofsky performance score 81±15.3 20–100
Medical risk factors
Diabetes mellitus 6 (14)
Peripheral vascular disease 2 (5)
Myelosuppression 2 (5)
Surgical risk factors
Opening of the ventricles 13 (30)
Dural patch required 28 (64)
Planned partial resection 6 (14)
Perioperative antibiotics 37 (84)
Neurosurg Rev (2010) 33:441–449 44315.6 months (Table 2). Postoperative KPS at the time of
discharge compared to hospital admission had improved in
six patients (14%), remained unchanged in 29 patients
(66%), and decreased in nine patients (20%). Ten patients
(23%) were scheduled for reoperation because of tumor
progression during the evaluation period (mean time to
reoperation 8.6±4.8 months).
Adverse events
AE of any kind were reported for a total of 23 patients
(52%) and resulted in therapy delays for concomitant
radiochemotherapy in eight patients (18%) and a deferred
start of subsequent temozolomide monochemotherapy in
four patients (9%; Fig. 1). Surgical adverse events included
wound healing abnormalities and local wound infections
(seven patients, 16%), CSF leakage (five patients, 11%),
meningitis (three patients, 7%), intracranial abscess forma-
tion (two patients, 5%), cerebral edema (11 patients, 25%),
and hydrocephalus (three patients, 7%). Conservative
treatment of surgical adverse events included lumbar
drainage for CSF leaks, steroids for edema, and i.v.
antibiotics for meningitis. Unscheduled readmission to the
hospital was required for 19 patients (43%), and surgical
intervention was necessary in seven patients (16%). Further
details for incidence, severity, and treatment of documented
adverse events are shown in Table 3.
Neurological AE included new onset seizures (seven
patients, 16%), mental alteration (eight patients, 18%), and
new neurological deficits (five patients, 11%). Corresponding
medical treatment was carried out in all cases.
Prophylactic subcutaneous low molecular weight heparin
or i.v. heparin was administered in all patients. Medical
adverse events were reported in seven patients (16%)
including thrombosis (four patients, 9%) and pulmonary
embolism (three patients, 11%). One patient suffered a
grade 5 thromboembolic event and died because of
pulmonary embolism following deep venous thrombosis
during the course of postoperative radiation therapy.
NCI grade 4 leucopenia was observed in one patient
(2%) and grade 3 thrombopenia in two patients (5%). One
patient with preexisting myelosuppressive disease required
readmission for blood transfusion; other patients with low
red or white blood counts did not require transfusion or
readmission (Table 3).
With respect to time of occurrence of adverse events, it
was of interest that complications occurred in 57% (13
patients) during the postoperative concomitant radiochemo-
therapy course and in 39% later on after completion of
radiochemotherapy. Only one patient (4%) was diagnosed
with a CSF leak during the immediate postoperative period
at day 6 (Fig. 2).
No significant difference in type or frequency of adverse
events between the different centers was noted. No
significant correlation of preexisting risk factors like age,
KPS, diabetes, vascular or myelosuppressive diseases, and
the incidence of adverse events was observed. Further, no
significant impact of surgical techniques such as dural
repair, intraoperative opening of the ventricular system, or
perioperative administration of antibiotics was noted.
Survival and progression
The median OAS in our patient population at time of adverse
event analysiswas 12.7months(Fig.3). However, at the time
of data summary, 16 patients (36%) were still alive and 15
patients showed no evidence of clinical or radiographic
progression. Clinical progression was documented for 30
patients (68%), and MRI follow-up showed radiographic
progression in 18 patients (41%). The median follow-up for
all patients alive was 15.6 months. The 12-month OS rate
was 58% and median PFS was 7.0 months with a 6-month
PFS/12-month PFS rate of 63% and 35%, respectively.
Discussion
Recently, we have presented a review of the literature from
1996 to February 2008 on the safety of BCNU wafer in
no AE
48% of patients
AE resulting 
in no treatment delay
25% of patients
AE leading to
delay in concomittant 
radiochemotherapy
18% of patients
AE leading to 
delay in 
TMZ monochemotherapy
9% of patients
Fig. 1 Impact of AE on treatment schedule
Table 2 Follow-up and outcome
Median follow-up
(15.6months)
Median OAS
(months)
Median PFS
(months)
Patients
Died 28 (64%) 10.7 6.0
Alive 16 (36%) 13.8 12.7
All 44 12.7 7.0
444 Neurosurg Rev (2010) 33:441–449newly diagnosed and recurrent malignant glioma patients.
Three pivotal clinical phase III trials and 26 non-phase
III studies were analyzed. The treatment experience for
implantation of BCNU wafers in patients with newly
diagnosed malignant glioma and patients with recurrent
disease were surveyed, and the overall incidence of
adverse events was summarized [19]. BCNU wafer group
AE rates from the pivotal phase III trials for newly
diagnosed glioblastoma ranged from 4% to 23% for
cerebral edema, 4% to 9% for intracranial hypertension,
14% to 16% for healing abnormalities, 5% for CSF leaks,
4% to 5% for intracranial infection, 19% to 33% for
seizures, 10% for deep vein thrombosis, and 8% for
pulmonary embolus. For newly diagnosed disease, statis-
tically significant differences between BCNU wafer
treatment and the placebo groups were observed only for
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Fig. 2 Time course of AE occurrence in 44 patients
Table 3 Adverse events
Type of AE Overall
incidence (%)
b
AE number of
observations
c
AE requiring
readmission [n (%)]
d
AE conservative treatment
alone [n (%)]
d
AE requiring surgical
intervention [n (%)]
d
52 23 19 (43) 16 (36) 7 (16)
Surgical/implantation site
Cerebral edema 25 11 7 (64) 11 (100) –
Healing abnormalities 16 7 6 (86) 3 (43) 4 (57)
CSF leak 11 5 5 (100) 3 (60) 2 (40)
Meningitis 7 3 2 (67) 3 (100) –
Intracranial abscess 5 2 2 (100) – 2 (100)
Hydrocephalus 7 3 2 (67) 2 (67) 1 (33)
Neurological
New seizures 16 7 7 (100) 7 (100) –
Alteration of mental status 18 8 6 (75) 8 (100) –
New neurological deficits 11 5 2 (40) 5 (100) –
Medical
Deep vein thrombosis 9 4 3 (75) 4 (100) –
Pulmonary embolism 7 3 3 (100) 3 (100) –
Leucopenia
a 21– 1 (2) –
Thrombocytopenia
a 5 2 1 (50) 2 (100) –
Anemia
a ––– – –
aNCI grades 3 and 4
bn=44 patients for the denominator
cIn 44 patients
dAE number of observations for the denominator
Neurosurg Rev (2010) 33:441–449 445intracranial hypertension which occurred at >6 months
following implantation in nine of the 11 patients in BCNU
wafer-treatedpatients.Thiswas attributedtotumor recurrence
and subsequent mass effect. CSF leak was more common in
the BCNU wafer group than in the placebo wafer group, but
did not reach statistical significance [25]. However, for both
BCNU wafer and placebo wafer treatment, wound healing
abnormalities and cerebral edema seemed higher than
expected in a general population of brain tumor patients
undergoing craniotomy. This may not be unexpected, as
animal studies have reported an inflammatory response to
blank polyanhydride copolymers [23].
In the phase III trial enrolling patients with recurrent
malignant gliomas, the overall incidence of serious intra-
cranial infection was more common with BCNU wafer
treatment (four out of 110, 4%) compared with placebo
(one out of 112, 1%), although the difference was not
statistically significant [2]. However, there was a significant
difference in the incidence of wound healing abnormalities
(14% for the BCNU wafer group and 5% for the placebo
wafer group; p<0.05). While similar proportions of patients
had seizures postoperatively, there was a difference in the
proportion of patients experiencing new or worsened
postoperative seizures early postoperatively. There were
no differences in AE rates between the three phase III
studies and 26 non-phase III studies. For the non-phase III
studies, the overall incidence of AE was low, ranging from
0.2% for intracranial hypertension to 9.6% for healing
abnormalities. Healing abnormalities, intracranial infection,
and seizures were the most consistently reported AE [5, 14,
26]. Rates of healing abnormalities appeared higher in
recurrent than in newly diagnosed disease [19].
While data from the Gliadel phase III studies suggested
that BCNU wafer is generally well tolerated and effective,
its use has evolved in the context of new treatment
standards for malignant gliomas. Currently, most patients
receiving BCNU wafer will also receive radiation and
systemic chemotherapy, as part of multimodal treatment
strategies. This has led to combination of BCNU wafer with
brachytherapy [4, 19, 27], radiosurgery [1, 7, 10, 12, 19,
20], and systemic therapies including irinotecan, lomustine,
procarbazine, carboplatin, interferon, and temozolomide [9,
11]. However, multimodal treatment strategies carry the
potential of additive toxicity and therefore have to be
evaluated extremely carefully. Temozolomide is the most
recent agent that has proven efficacy in the treatment of
malignant gliomas. Temozolomide was shown to signifi-
cantly prolong survival in patients with newly diagnosed
malignant gliomas and is generally well tolerated, with
hematologic toxicity being the most notable safety issue
[22]. The combination of local BCNU wafer treatment and
systemic temozolomide has not been assessed in phase III
trials, but recently, some non-phase III studies have
investigated the efficacy and safety of BCNU wafer and
temozolomide within multimodal treatment strategies [1, 7,
10, 19]. There were no unexpected AE reported in the
BCNU wafer and temozolomide studies. Compared to
known AE associated with BCNU wafer treatment, the
added hematological toxicity at a median rate of 14.8%
(7.1–53.3%) was comparable to grade 3 or 4 hematologic
toxic events reported in the phase III study for temozolo-
mide alone [22]. Combining local and systemic treatment
strategies is tempting. However, elevated complication rates
may lead to delays in oncological treatment and may even
result in early termination of treatment plans. The risk/
benefit ratio for these intense multimodal treatments has
therefore to be assessed very carefully. In contrast to the
few other studies investigating intraoperative BCNU wafer
treatment followed by postoperative radiation therapy and
concomitant temozolomide and subsequent temozolomide
monochemotherapy, our multicenter study focused on the
retrospective analysis of AE specifically and was not
designed nor powered to demonstrate treatment efficacy.
Inclusion of patients with newly diagnosed glioblastoma for
analysis of treatment-related adverse events was based on
the treatment decision of the individual center. No other
Median OAS (months)           12.7  
12-months OAS- rate (%)       58 
24-months OAS- rate (%)       13 
Median PFS (months)           7.0  
6-months PFS- rate (%)         63 
12-months PFS- rate (%)        35
0
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Fig. 3 Survival and progression
in 44 glioblastoma patients
treated with carmustine
wafers and concomitant
radiochemotherapy
446 Neurosurg Rev (2010) 33:441–449formal inclusion criteria such as age, neurological perfor-
mance score, or feasibility of a gross total resection applied.
Therefore, this patient population is likely to represent a
negative selection bias in terms of prognosis and treatment
risk compared to phase III trials or other studies (compare
material and methods section). However, this patient
population is likely to reflect a cohort requiring treatment
in every day neuro-oncology practice. In this patient
population, our analysis suggests a higher rate of AE
compared to the data published for the BCNU wafer phase
III trials [15, 16]. We found an elevated incidence of
intracranial infections and CSF leaks (Table 4) compared to
a recently published study [19] that reported a compara-
tively low incidence of adverse events for BCNU wafer
treatment and concurrent temozolomide. Only three of 21
patients experienced toxic side effects. A recent report on a
similar phase II study [10] reported an overall high rate of
adverse events (20 of 35 patients), but did not specifically
report on wound healing abnormalities. One intracranial
abscess was reported in the later analysis. However, there
was an unexpected rate of thromboembolic events (deep
vein thrombosis in five and pulmonary embolism in four of
35 patients), respectively. A study designed to specifically
analyze adverse events is likely to find an elevated rate of
such events. The non-phase III studies cited above focused
on treatment efficacy and did not present clear criteria for
adverse event reporting. In this study, 23 patients (52%)
experienced adverse events of any kind which included
complications that did not require specific treatment.
Nineteen patients (43%) experienced grade 3 or grade 4
adverse events including hematotoxic events. This com-
pares to 16% grade 3 or grade 4 events for concomitant
radiochemotherapy [22] added to the adverse events
reported in the phase three trials for local BCNU chemo-
therapy followed by radiation. These trails did not report
how many patients experienced grade 3 or grade 4 adverse
events, but rather presented rates for specific events, for
example, 16% wound healing, 5% intracranial infection,
and 33% seizures [25]. Therefore, it is difficult to estimate
the additional risk of the multimodal approach studied here.
In our study for eight patients (18%), AE resulted in the
delay of radiochemotherapy, and for four patients (9%), AE
lead to delay of further oncological treatment. It is likely
that surgical strategies or preexisting medical conditions
impact on the incidence of adverse events. Surprisingly, this
was not observed in our study. Frequency and type of
adverse events were independent of age, preoperative
clinical condition, surgical strategy, or the institution at
which patients were treated. Interestingly, all adverse events
registered in this study occurred after scheduled discharge
from hospital and during the first 2 to 3 months after
BCNU wafer implantation. In 19 patients (43%), readmis-
sion in a neurosurgical center was required, and specific
neurosurgical intervention was necessary in seven patients
(16%). Because most adverse events occurred during
concomitant radiochemotherapy or through the first cycles
of temozolomide monochemotherapy, the relatively short
follow-up of this study seems to be sufficient to evaluate
the risk of AE under this treatment regimen. Our study
suggests that the incidence of adverse events associated
with BCNU wafer treatment in combination with concur-
rent radiation and temozolomide chemotherapy is currently
underestimated. We have therefore recently conducted a
comprehensive review of the literature on individual
adverse events associated with carmustine wafer implanta-
tion reported in the literature and the proposed avoidance
Table 4 Incidence of AE compared
Type of AE Overall incidence (%) Overall incidence (%) Overall incidence (%)
Newly diagnosed GBM BCNU
wafer+radiation+TMZ chemotherapy
(n=44 patients)
Newly diagnosed GBM pivotal
phase III trial BCNU wafer
reatment group (n=120 patients)
a
Selected non-phase III clinical
studies of BCNU wafer treatment
in newly diagnosed and recurrent
malignant gliomas (n=887 patients)
b
Healing abnormalities 16 16 9.6
CSF leak 11 5 2.1
Intracranial infection 9 5 2.4
Thromboembolic events
Deep vein thrombosis 9 10 1.6
Pulmonary embolism 7 8 1.0
Hematotoxic events
NCI grades 3 and 4 5 0 Not analyzed
aWestphal et al. [25]
bSabel and Giese [19]
GBM glioblastoma multiforme
Neurosurg Rev (2010) 33:441–449 447strategies [6]. Based on the reported incidence and the time
course of adverse events, we have proposed a formal
protocol for patient selection, surgical techniques, and
follow-up schedules for patients scheduled for carmustine
wafer implantation at our institution. Following introduc-
tion and strict adherence to this risk management protocol,
specifically implantation site-related complications dropped
significantly [6]. Our study further demonstrates that
several adverse events occur late after initial surgery and
wafer implantation (compare Fig. 2). Most adverse events,
including wound healing abnormalities and intracranial
infections, occurred after patients had been discharged from
neurosurgical units and manifested at a time when patients
were not under direct care of their surgeons. Therefore, the
neuro-oncological follow-up schedule was now modified to
account for late wound healing complications [6].
Conclusion
The efficacy of BCNU wafer treatment followed by radiation
chemotherapy within multimodal treatment strategies to day
remains unproven and therefore has to be considered an
experimentaltreatmentstrategy.The safetydataprovidedhere
suggest that BCNU wafer treatment followed by radiation
chemotherapy requires further validation of risk management
strategies. The use of BCNU wafer with radiation and
concurrent temozolomide followed by temozolomide mono-
chemotherapy does not appear to result in new types of AE.
However, clinicians should be aware of the potential risks
associated with BCNU wafer.
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Comments
Miguel A. Arraez, Malaga, Spain
The article written by Bock and colleagues is focusing on the
treatment of malignant gliomas by means of surgery, BCNU wafers in
the tumoral bed, radiotherapy, and temozolomide. The addition of
BCNU wafers as local therapy has been proven useful in malignant
gliomas, although with untoward side effects. The Stupp scheme
(radiation therapy and concomitant temozolomide/6 weeks radio-
chemotherapy followed by six cycles of temozolomide monochemo-
therapy) has also shown its potential to prolong survival in these
patients. The current management of malignant gliomas varies
according patients and centers, but it is important to notice that
nowadays many patients undergo resection and receive BCNU wafers
and after discharge from hospital, radiotherapy plus temozolomide is
administered. In this paper, Bock et al. do state that the main aim of
this study is not the survival analysis but the adverse effects of such a
combination of treatments. This is a very important endpoint for the
analysis. The results of Bock and colleagues show a surprisingly high
rate of complications and adverse effects, more than probably
suspected, when the above-mentioned combination of treatments is
used. It calls also the attention of the high number of thromboembolic
events in this subset of patients. It is not known whether this series of
patients did receive or not prophylaxis with heparin.
The results of this study suggest that a further selection of patients
to follow this scheme should be regarded, as the risk/benefits ratio
could not be the same for all patients. According to this consideration,
some stratification could be made in the future taking into account
survival and adverse events for obvious purposes of model prediction
before undertaking the combination of surgery, BCNU wafers,
radiation, and temozolomide.
Oliver Heese, Hamburg, Germany
The currently available standard for the treatment of glioblastoma
consists of gross total resection followed by concomitant radiation
therapy/chemotherapy with temozolomide followed by cyclic temo-
zolomide for 6 months resulting in an overall survival of 14 to
15 months with an acceptable side effect spectrum. In theory,
intensifying this regimen by adding a local chemotherapy may lead
to a prolonged survival, in particular since time from surgery to the
beginning of radiation therapy is without any further treatment so far.
In this nicely written manuscript, a multicenter approach was taken to
gain information regarding the number and severity of adverse events
of a “first-line treatment of malignant glioma with carmustine implants
followed by concomitant radiochemotherapy”. In 44 patients, the
adverse events were collected retrospectively. Treatment efficacy data
were not the intention of the study due to the retrospective and
unrandomized trial design, but a median overall survival of
12.7 months and a median progression-free survival of 7.0 months
were seen.
Regardingthe number ofadverseevents,52% ofpatientsexperienced
adverse events of any kind including complications not needing further
treatment, and in 43% of patients’ adverse events, grades 3 and 4 were
seen. The authors summarize that a combination of local chemotherapy
and concomitant radiochemotherapy carries a significant risk of toxicity
that may have been underestimated currently.
In conclusion, these data definitely lead to caution when planning
new therapy protocols for malignant glioma treatment. It seems that
1+1 is not always 2 and combining different therapy regimens, in
theory from a pathophysiological perspective working synergistically,
may lead to an increased and unacceptable side effects spectrum.
Taking into account that all of these therapies are only performed in
a palliative setting and so far the overall survival for glioblastoma
multiforme (GBM) is still only approximately 14 month, severe side
effects leading to hospitalization and profound loss of quality of life
are unacceptable for patients and their families. For further study
designs, focusing only on endpoints like overall survival and
progression-free survival may not be adequate, and adding quality
of life assessments and other psycho-oncological criteria seems to be
mandatory in order to do the best for GBM patients.
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